hemotune raises CHF 14 million Series B2 funding for clinical trials with the HemoSystem
News 26.03.2024 Schlieren, Switzerland, March 25th, 2024 – hemotune AG, a pioneering Swiss biotech company, today announced the successful closing of a CHF 14 million Series B2 round dedicated to advancing its HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads. The investment was led by Belmondo with continued support of...